Japan
· Delayed Price · Currency is JPY Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of JPY 2.50 trillion. The enterprise value is 3.14 trillion.
| Market Cap | 2.50T |
| Enterprise Value | 3.14T |
Important Dates
The next estimated earnings date is Friday, August 1, 2025.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | Mar 28, 2025 |
Share Statistics
Astellas Pharma has 1.79 billion shares outstanding. The number of shares has decreased by -0.14% in one year.
| Current Share Class | 1.79B |
| Shares Outstanding | 1.79B |
| Shares Change (YoY) | -0.14% |
| Shares Change (QoQ) | +1.59% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 55.58% |
| Float | 1.79B |
Valuation Ratios
The trailing PE ratio is 49.43 and the forward PE ratio is 18.46. Astellas Pharma's PEG ratio is 0.24.
| PE Ratio | 49.43 |
| Forward PE | 18.46 |
| PS Ratio | 1.31 |
| PB Ratio | 1.65 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.87 |
| P/OCF Ratio | 12.85 |
| PEG Ratio | 0.24 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.28, with an EV/FCF ratio of 19.95.
| EV / Earnings | 61.92 |
| EV / Sales | 1.64 |
| EV / EBITDA | 7.28 |
| EV / EBIT | 13.53 |
| EV / FCF | 19.95 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.55.
| Current Ratio | 1.13 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 1.93 |
| Debt / FCF | 5.28 |
| Interest Coverage | 13.16 |
Financial Efficiency
Return on equity (ROE) is 3.26% and return on invested capital (ROIC) is 5.98%.
| Return on Equity (ROE) | 3.26% |
| Return on Assets (ROA) | 4.21% |
| Return on Invested Capital (ROIC) | 5.98% |
| Return on Capital Employed (ROCE) | 10.21% |
| Revenue Per Employee | 129.61M |
| Profits Per Employee | 3.44M |
| Employee Count | 14,754 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.45% in the last 52 weeks. The beta is 0.13, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -12.45% |
| 50-Day Moving Average | 1,385.56 |
| 200-Day Moving Average | 1,557.40 |
| Relative Strength Index (RSI) | 49.58 |
| Average Volume (20 Days) | 5,279,840 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of JPY 1.91 trillion and earned 50.75 billion in profits. Earnings per share was 28.24.
| Revenue | 1.91T |
| Gross Profit | 1.56T |
| Operating Income | 232.55B |
| Pretax Income | 31.24B |
| Net Income | 50.75B |
| EBITDA | 431.68B |
| EBIT | 232.55B |
| Earnings Per Share (EPS) | 28.24 |
Balance Sheet
The company has 188.37 billion in cash and 831.43 billion in debt, giving a net cash position of -643.05 billion or -359.23 per share.
| Cash & Cash Equivalents | 188.37B |
| Total Debt | 831.43B |
| Net Cash | -643.05B |
| Net Cash Per Share | -359.23 |
| Equity (Book Value) | 1.51T |
| Book Value Per Share | 845.21 |
| Working Capital | 139.74B |
Cash Flow
In the last 12 months, operating cash flow was 194.51 billion and capital expenditures -37.00 billion, giving a free cash flow of 157.51 billion.
| Operating Cash Flow | 194.51B |
| Capital Expenditures | -37.00B |
| Free Cash Flow | 157.51B |
| FCF Per Share | 87.99 |
Margins
Gross margin is 81.74%, with operating and profit margins of 12.16% and 2.65%.
| Gross Margin | 81.74% |
| Operating Margin | 12.16% |
| Pretax Margin | 1.63% |
| Profit Margin | 2.65% |
| EBITDA Margin | 22.57% |
| EBIT Margin | 12.16% |
| FCF Margin | 8.24% |
Dividends & Yields
This stock pays an annual dividend of 78.00, which amounts to a dividend yield of 5.59%.
| Dividend Per Share | 78.00 |
| Dividend Yield | 5.59% |
| Dividend Growth (YoY) | 5.71% |
| Years of Dividend Growth | 9 |
| Payout Ratio | 254.19% |
| Buyback Yield | 0.14% |
| Shareholder Yield | 5.73% |
| Earnings Yield | 2.03% |
| FCF Yield | 6.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.
| Last Split Date | Mar 27, 2014 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Astellas Pharma has an Altman Z-Score of 2.1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.1 |
| Piotroski F-Score | n/a |